Abstract
Objective: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients. Research design and Methods: A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months. Main outcome measures: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. Results: After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better. Conclusion: Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.
| Original language | English |
|---|---|
| Pages (from-to) | 2581-2591 |
| Number of pages | 11 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 13 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - Dec 2012 |
Fingerprint
Keywords
- Chemerin
- Metformin
- RBP-4
- Resistin
- TNF-α, vildagliptin
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients : A 12-month, placebo-controlled study. / Derosa, Giuseppe; Ragonesi, Pietro D.; Carbone, Anna; Fogari, Elena; D'Angelo, Angela; Cicero, Arrigo Fg; Maffioli, Pamela.
In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 18, 12.2012, p. 2581-2591.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vildagliptin action on some adipocytokine levels in type 2 diabetic patients
T2 - A 12-month, placebo-controlled study
AU - Derosa, Giuseppe
AU - Ragonesi, Pietro D.
AU - Carbone, Anna
AU - Fogari, Elena
AU - D'Angelo, Angela
AU - Cicero, Arrigo Fg
AU - Maffioli, Pamela
PY - 2012/12
Y1 - 2012/12
N2 - Objective: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients. Research design and Methods: A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months. Main outcome measures: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. Results: After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better. Conclusion: Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.
AB - Objective: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients. Research design and Methods: A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months. Main outcome measures: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. Results: After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better. Conclusion: Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.
KW - Chemerin
KW - Metformin
KW - RBP-4
KW - Resistin
KW - TNF-α, vildagliptin
UR - http://www.scopus.com/inward/record.url?scp=84870201257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870201257&partnerID=8YFLogxK
U2 - 10.1517/14656566.2012.734499
DO - 10.1517/14656566.2012.734499
M3 - Article
C2 - 23121473
AN - SCOPUS:84870201257
VL - 13
SP - 2581
EP - 2591
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 18
ER -